Compass

HEALTH, MARGINALLY CHEAPER

02/10/19 -"The Health (ex Pharma) sector has lost ground over the last month but this reflects more a risk-on market context than a genuine sell-off in this expensive territory. Health stocks have been losing ..."

PDF page sample
Pages
49
Language
English
Published on
02/10/19
Download
You may also be interested by these reports :
16/10/25
FDJ United delivered softer than expected Q3 2025 results as tax and regulatory headwinds, and unfavourable sports results weighed heavily on its ...
16/10/25
Whitbread’s share price fell by 10% following its H1 results. Although the softness largely reflected the temporary impact of the Accelerating Growth ...
16/10/25
Entain’s Q3 2025 update highlighted steady underlying progress across its core operations and a clear turning point in the US. Group NGR rose 7%, led ...
15/10/25
OPAP is merging with its controlling shareholder, Allwyn, in an all-share deal to create a €16 billion gambling powerhouse, the second-largest listed ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO